CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicExploring Cutaneous Drug-Related and Drug-Associated Adverse Events: From Clinical Insight to Therapeutic ManagementView all 8 articles
Severe Systemic Cutaneous Adverse Reactions Following Camrelizumab Therapy: A Case Report and Literature Review
Provisionally accepted
- 1Cancer Research Institute, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China
- 2Xinjiang Key Laboratory of Translational Biomedical Engineering, Urumqi, China
- 3Shandong First Medical University, Tai'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
We report a case of a 42-year-old female patient with lip squamous cell carcinoma who developed a severe systemic cutaneous adverse reaction following camrelizumab therapy. The patient had previously undergone wide local excision, chemotherapy, and radiotherapy before receiving camrelizumab in combination with transcatheter arterial chemoembolization. Ten days after the initial infusion, she presented with generalized desquamation, hyperpigmented lesions, and skin breakdown involving the trunk and extremities, most prominently on the hands, arms, and legs. Corticosteroid therapy led to a rapid reduction in pruritus and gradual improvement of cutaneous lesions, with marked healing observed after one week. Remarkably, upon rechallenge with camrelizumab, only mild residual hyperpigmentation was noted without recurrence of severe symptoms. This case highlights the importance of recognizing camrelizumab-associated dermatologic toxicity, emphasizes the role of timely corticosteroid intervention, and suggests that cautious rechallenge may be feasible in selected patients. Further investigation is warranted to elucidate the immunopathological mechanisms underlying severe skin reactions to PD-1 inhibitors and to optimize prevention and management strategies.
Keywords: camrelizumab, immune checkpoint inhibitors, severe cutaneous adverse reaction, Squamous cell carcinoma, Corticosteroid management
Received: 27 Sep 2025; Accepted: 25 Nov 2025.
Copyright: © 2025 Sun, Guo and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jian-Jun Han
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.